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Abstract
Objective Randomised controlled trials have shown a reduction in breast cancermortality frommammography screening and it is
the detection of high-grade invasive cancers that is responsible for much of this effect. We determined the detection rates of
invasive cancers by grade, size and type of screen and estimated relative sensitivities with emphasis on grade 3 detection.
Methods This observational study analysed data from over 11 million screening episodes (67,681 invasive cancers) from the
English NHS breast screening programme over seven screening years 2009/2010 to 2015/2016 for women aged 45–70.
Results At prevalent (first) screens (which are unaffected by screening interval), the detection rate of small (< 15 mm) invasive
cancers was 0.95 per 1000 for grade 1, but for grade 3 only 0.30 per 1000. The ratio of small (< 15 mm) to large (≥ 15 mm)
cancers was 1.8:1 for grade 1 but reversed to 0.5:1 for grade 3. We estimated that the relative sensitivity for grade 3 invasive
cancers was 52% of that for grade 1 and the relative sensitivity for small (< 15 mm) grade 3 only 26% of that for small (< 15 mm)
grade 1 invasive cancers.
Conclusions Sensitivity for small grade 3 invasive cancers is poor compared with that for grade 1 and 2 invasive cancers and
larger grade 3 malignancies. This observation is likely a limitation of the current technology related to the absence of identifiable
mammographic features for small high-grade cancers. Future work should focus on technologies and strategies to improve
detection of these clinically most significant cancers.
Key Points
• The detection of small high-grade invasive cancers is vital to reduce breast cancer mortality.
•We estimate the sensitivity for small grade 3 invasive cancers may be only 26% of that of small grade 1 invasive cancers. This is
likely to be associated with the non-specific mammographic features for these cancers.
• New technologies and appropriate strategies using current technology are required to maximise the detection of small grade 3
invasive cancers.
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Abbreviations
DCIS Ductal carcinoma in situ
HNG High nuclear grade
NBSS National Breast Screening System
NHSBSP National Health Service Breast
Screening Programme
PHE Public Health England
Introduction
Breast cancer is the world’s second largest cause of female
cancer death after lung cancer despite the introduction of
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breast cancer screening and improved treatment. Whilst the
benefits of screening in terms of mortality reduction have been
accepted, there is still disagreement over the magnitude of the
effect [1–3]. This also applies to overdiagnosis and the com-
peting effects of screening and early symptomatic detection in
the light of modern treatment [4–6].
Many of the UK screening programme performance
measures are based on the Swedish Two County (STC)
randomised controlled trial which demonstrated the im-
portance of detecting small-grade 3 invasive cancers [7].
Porter [8] found that most interval cancers (those clinical-
ly presenting between screens) are grade 3 or grade 2 and
that only a small proportion of interval cancers are grade
1. Perron [9] has similarly shown that the sensitivity of
screening in Quebec is lowest for the most aggressive
phenotypes and that this effect is mediated by grade.
This reinforces the STC message that at least 30% of
the screen-detected grade 3 invasive cancers should be
< 15 mm in diameter [10] when they are less likely to
have nodal involvement.
New digital technology has increased the detection rate
of high-grade DCIS, grade 1 invasive cancers and grade 2
invasive cancers, but has not impacted the grade 3 detec-
tion [11]. To date in England, we have no data on change
in interval cancers related to the introduction of digital
mammography. Tomosynthesis [12, 13] has simulta-
neously increased cancer detection rate and in low-
specificity programmes, it has reduced recall rates. None
of the studies, to date, has been powered to measure in-
terval cancer rates but initial reports have shown minimal
if any reduction [14]. The information on grade distribu-
tion of the cancers detected suggests a preferential detec-
tion for lower grade disease [14, 15]. Both screen detec-
tion rates and interval cancer rates therefore indicate a
high sensitivity for lower grade invasive cancers.
However, if we are to further improve performance and
increase mortality reduction, we need to understand the
limitations of current technology and the ability of new
technology to detect small grade 3 cancers.
A high sensitivity for a grade of cancer at screening is
indicated by a high detection of small cancers of that
grade and low detection of interval cancers of that grade.
This paper examines 7 years of screening data from 2009/
2010 to 2015/2016 to determine the invasive cancer de-
tection rate by grade and size in the English NHS breast
cancer screening programme (NHSBSP) with a particular
emphasis on grade 3 invasive cancers. We use our large
dataset to explore relative sensitivity using detection rates
at prevalent (first) and incident (subsequent) screens. The
former are particularly important as they are not influ-
enced by screening interval and therefore can give greater
insight into the detection of small grade 3 cancers using
current technology.
Methods
This study was undertaken using data from an ongoing
population-based breast screening programme for asymptom-
atic women aged 50–70. Since 2010 as part of the AgeX trial
[16], first invitations now occur in the age range 45–52 years.
The NHSBSP uses a single national information technology
system (NBSS) and collects standardised data on all breast
screening activity which is published annually [17]. The
NHSBSP has gained approval to access and process patient
data for the purposes of quality control under section 251 of
the Health and Social Care Act 2008 through the approval of
the Confidentiality Advisory Group (previously the National
Information Governance Board for Health and Social Care).
Because this study did not involve patient contact, interven-
tion or use of identifiable patient data, it was determined to be
exempt from human subject’s ethical review in the UK. Ethics
committee approval was therefore not required and the need
for written informed consent was waived.
The NHSBSP is a large nationally organised programme
where equipment and techniques are standardised. Women
eligible for breast screening are identified from the NHS da-
tabase and invited 3 yearly by one of the 80 breast screening
facilities in England. Each facility has a static (hospital-based)
unit and several mobile vans or satellite facilities each with a
mammography unit. Bilateral two-view mammography is in-
dependently double-read by film readers with defined national
standards for training, caseloads and performance. Arbitration
is undertaken for cases where there is a discrepancy between
the reader’s opinions. Women recalled for further investiga-
tion (assessment) attend the responsible screening service.
Assessment is conducted according to the national guidance
and all women undergoing biopsy are discussed at multidis-
ciplinary team meetings [18, 19].
Study population
Numbers of women screened, and cancers detected are taken
from the National Korner (KC62) returns sent to Public Health
England (PHE) annually for the 80 screening facilities follow-
ed over the seven screening years 2009/2010 to 2015/2016.
Over the study period, it is estimated that 65% of mammo-
grams were taken using digital mammography and the rest
analogue screen film [11]. Information on the grade and size
of invasive cancers is taken from the KC62 annex. The data
used are for all routine prevalent (first) screens at ages 45–
52 years and incident screens (subsequent) at ages 53–
70 years to allow for greater comparability between facilities.
All women who underwent their first screen after previously
being invited and not attending were excluded. Interval cancer
data for this period is not yet available so it is not possible to
calculate absolute sensitivity, and estimates of relative sensi-
tivity have been made using published data [8].
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Statistical methods
Statistical tests are given where considered useful. Funnel
plots of individual unit data comparison show 95% and
99.8% control limits. All graphs and statistical analysis use
STATA version 14.
Results
Over the 7 screening years 2009/2010 to 2015/2016, there
were a total of 11,258,620 eligible screening attendances
and 86,443 (7.7 per 1000) cancers were detected of which
67,681 (6.0 per 1000) were invasive. Of the invasive cancers,
65,509 (97%) had both size and grade recorded.
Detection rates by size and grade
Table 1 and Fig. 1 show details of the observed number and
rate of invasive cancers with both size and grade is recorded.
At prevalent screens, the rate of large (≥ 15 mm) invasive
cancers was 0.52 per 1000 women for grade 1, 1.49 per
1000 for grade 2 and 0.62 per 1000 at grade 3 at age approx-
imately 50 years, which is also the underlying rate of disease
for large cancers assuming close to 100% sensitivity (see the
“Discussion” section). The ratio of small to large invasive
cancers is a key indicator of the ability of screening to detect
small invasive cancers. At prevalent screens (which are not
affected by screening interval), the detection rate of small
grade 1 cancers (0.95 per 1000) is nearly double (1.8:1) that
of large tumours (0.52 per 1000). However, this ratio reverses
for grade 3 cancers (0.5:1) where large cancers at prevalent
screens (0.62 per 1000) are found at over double the rate of
small cancers (0.30 per 1000). This contrasts with the grade 1
data and suggests that there is a large pool of undetected small
grade 3 invasive cancers and therefore that mammography has
a much lower sensitivity for small grade 3 invasive cancers.
For incident screens, the detection of invasive cancers is a
function of the numbers removed from the system by the earlier
screens, the growth rate of the cancers and screening sensitivity.
The highest detection rate at incident screens is for small (<
15mm) grade 2 invasive cancers at 1.70 per 1000 and the lowest
detection rate is for large (≥ 15mm) grade 1 invasive cancers. At
incident screens, the detection rate of small (< 15 mm) grade 1
invasive cancers is 1.14 per 1000 compared with 0.37 per 1000
for large grade 1 cancers (≥ 15 mm), a ratio of 3.1:1. The ratio is
again reversed for grade 3 invasive cancers where it is 0.7:1.
To provide more detail, Fig. 2a and b show histograms of
the size distribution of invasive cancers at prevalent and inci-
dent screens by grade with mean size at each grade shown by
the vertical line. At prevalent screens, the mean size of a
screen-detected grade 1 invasive cancer (13.7 mm) is less than
the mean size of grade 2 invasive cancers (19.0 mm) and grade
3 invasive cancers (21.4 mm). These differences are highly
significant (p < 0.001). Similar results are seen for incident
screens where the mean sizes of grades 1, 2, and 3 invasive
cancers are 11.6 mm, 16.7 mm and 19.0 mm respectively
(p < 0.001). Very few grade 1 invasive cancers are detected
at larger sizes, particularly at incident (subsequent) screens.
Close inspection of the histogram shows that fewer grade 3
invasive cancers are detected at less than 10 mm for either
prevalent (13%) or incident (16%) screens and this reduces
to very low numbers at less than 5 or 6 mm. At prevalent
screens, the percentage of invasive cancers of 1–5 mm is
12.1% for grade 1 cancers reducing to 7.4% for grade 2 and
only 4.3% for grade 3. Prevalent screen detection rates should
more closely reflect the distribution of underlying pre-clinical
disease and the finding of so few very small grade 3 invasive
cancers at prevalent screens suggests that grade 3 invasive
cancers at 1–5 mmmay therefore mostly be effectively occult.
Numerical estimates of relative disease sensitivity (from
prevalent screen data)
The growth of breast cancers is usually modelled using expo-
nential or Gompertz models [20]. Grade 3 invasive cancers
grow faster on average than other invasive cancers, but the
underlying model can be considered the same and therefore,
the proportion below a certain size will be the same (see the
“Discussion” section). To explore further, we make three as-
sumptions about the distribution of these invasive cancers: (a)
the relative size distribution of invasive cancers in unscreened
women (i.e. the distribution in the pre-clinical detectable
phase) should be approximately the same regardless of grade,
Table 1 Prevalent screen and incident screen association between size and grade for invasive cancers from 2,295,016 prevalent and 8,963,604 incident
screens with number, percentage and rate per 1000 (based on 65,509 (97%) of 67,681 invasive cancers with both size and grade recorded)
Grade 1 Grade 2 Grade 3 Total
< 15 mm 15 +mm < 15 mm 15 +mm < 15 mm 15 +mm
N (%), rate p 1000 N (%), rate p 1000 N (%), rate p 1000 N (%), rate p 1000 N (%), rate p 1000 N (%), rate p 1000 N (%), rate p 1000
Prevalent 2177 (19.0), 0.95 1192 (10.4), 0.52 2562 (22.4), 1.12 3414 (29.8), 1.49 682 (6.0), 0.30 1414 (12.4), 0.62 11.441 (100), 4.99
Incident 10,245 (19.0), 1.14 3295 (6.1), 0.37 15,231 (28.2), 1.70 14,036 (26.0), 1.57 4467 (8.3), 0.50 6794 (12.6), 0.76 54,068 (100), 6.03
Total 12,422 (19.0), 1.10 4487 (6.8), 0.40 17,793 (27.2), 1.58 17,450 (26.6), 1.55 5149 (7.9), 0.46 8208 (12.5), 0.73 65,509 (100), 5.78
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(b) most invasive cancers of size 15 mm and above are detect-
ed by mammography and (c) that progression of cancers from
lower to higher grades in these cancers is small. We can then
use these assumptions to make a simple estimation of the
relative sensitivity for grade 2 and grade 3 disease relative to
grade 1 (Table 2) at prevalent screens. The ratio of < 15mm to
≥ 15 mm grade 1 invasive cancers is 1.8:1 based on 2177
< 15 mm and 1192 ≥ 15 mm from Table 1). If we apply the
same ratio to grade 2 and grade 3 invasive cancers, the esti-
mated relative sensitivity for grade 2 relative to grade 1 is 62%
and for grade 3 relative to grade 1 is 52%. Relative sensitivity
for small (< 15mm) grade 2 and 3 cancers is lower at 42% and
26% respectively. Table 3 shows our estimation of relative
sensitivity along with estimations of relative sensitivity from
published information adapted from Porter et al [8] and Perron
et al [9] showing some agreement and therefore that such an
approach could be useful.
Individual facility detection rates
Figure 3 shows a histogram of the individual facility grade 3
(prevalent and incident combined) invasive cancer detection
rates for 80 screening facilities for the period 2009/2010 to
2015/2016. The mean rate was 1.22 per 1000 (SD 0.25) with a
range of 0.68 to 1.92. The 25th and 75th percentiles were 1.05
and 1.34. In total, there were 13,693 grade 3 invasive cancers
with 336 (2.5%) of unknown size. For cancers with known
size, the mean detection rate of < 15-mm invasive cancers was
0.46 per 1000 (SD 0.12) with a range of 0.22 to 0.87 per 1000.
Themean rate of ≥ 15-mm invasive cancers was 0.74 per 1000
(SD 0.18) with a range of 0.39 to 1.25 per 1000.
Figure 4 shows a funnel plot of the percentage of grade 3
invasive cancers with known size that are < 15 mm. This varies
from 21.5 to 53.7% with a mean of 38.4%. Whilst some facil-
ities have values below 30%, there are no facilities with a per-
centage of < 15-mm grade 3 invasive cancers below the lower
95% control limit of the 30% target suggested by Tabar et al
[10]. There are also no facilities with exceptionally high values,
the highest being around 50% and the distribution is normal
around the mean of 38.4%. The facilities all converted to digital
during the time period (mostly between 2010 and 2013) as per
the policy of the national programme as film mammography
units were replaced by digital mammography units gradually
within each facility. There were some differences in the propor-
tion of the study time period over which digital mammography
was used by different units. However, as there was no differ-
ence in the detection of grade 3 cancers between film and digital
[11], there would not be any confounding and the grade 3
detection rates between all units are therefore comparable.
Discussion
The importance of high-grade invasive cancer
detection
Mammography screening is proven in multiple RCTs to re-
duce breast cancer mortality [21] and the UK Independent
review estimates a 20% overall reduction in women invited
[2]. The mortality reduction is closely related to the detection
of grade 3 tumours and the Swedish two-county trial
outweighed that from detecting grade 1 and 2 cancers com-
bined despite fewer grade 3 cancers being detected [7]. High-
grade tumours are over-represented within interval cancers [8,
22] and the rate of interval cancers in England remains at
about 31 per 10,000 [23].
Fig. 1 Number of prevalent
screen invasive cancers by size
(< 15 mm or 15 +mm) for each
grade
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Sensitivity for small high-grade cancers compared
with historical data
In this retrospective observational study of the English
Breast Screening Programme, we provide evidence of a
relative lack of sensitivity for the detection of small grade
3 cancers estimated at only 26% of the sensitivity for
small grade 1 tumours. The sensitivity of mammographic
screening for these aggressive tumours may have changed
little since the early RCTs of screening where the Swedish
two-county RCT detected 37% of grade 3 cancers at less
15 mm [10]. Our data show a similar percentage (38.4%)
and that whilst individual facilities tend to have greater
than 30% of grade 3 invasive cancers detected at less than
15 mm, this target is based on mammography experience
during the 1970s. There is no evidence provided by this
data that the detection rate of grade 3 cancers is any better
than that achieved in the 1970s. In contrast, we have
strong evidence for substantial increases in the detection
of high-grade DCIS, grade 1 and some grade 2 invasive
cancers from technologies introduced since the beginning
of programme such as two-view mammography and dig-
ital imaging [11, 24–26].
Relatively few grade 1 cancers are detected at incident
screens which is likely to be a consequence of high detection
of grade 1 tumours at prevalent screens and slow growth rate.
Fig. 2 a Histogram of the size
distribution of invasive cancers
detected at prevalent screens by
grade (mean size 13.7, 19.0 and
21.4, one-way ANOVA
p < 0.001). b Histogram of the
size distribution of invasive can-
cers detected at incident screens
by grade (mean size 11.6, 16.7
and 19.0, one-way ANOVA
p < 0.001)
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Dataset
The origin of the data retrospectively from a national dataset does
limit the breadth of data that is available. For instance, bio-
markers and histological subtype categorisation such as triple
negative are not available. Grade does however remain a strong
prognostic indicator reflecting tumour aggressive potential [27]
and the size of the dataset from a nationally organised pro-
gramme where each site had similar techniques and equipment
is powerful as large numbers of grade 3 cancers are required to
produce the necessary level of statistical stability. In our dataset,
97% of invasive cancers had both grade and size recorded and
the missing size data was evenly distributed between grade 1, 2
and 3 cancers suggesting the missing data is unlikely to skew
results. Furthermore, with only 3% of invasive cancers not in-
cluded in our main tables, rates will be only very marginally
lower than if all invasive cancers had grade and size recorded.
Estimation of relative sensitivity at prevalent screen
Data on interval cancers for this period is not yet published so
we have been unable to calculate absolute sensitivity by grade
and size. We have estimated sensitivity relative to the
detection of grade 1 cancers based on a number of assump-
tions. The first assumption is that the relative size distribution
of tumours in an unscreened population is similar regardless
of grade. We assume that the same model e.g. exponential
model [20] applies to all grades independently and that the
proportion below a particular size is always the same. The
second assumption regarding detectability for all ≥ 15-mm
cancers does not consider problems of masking by dense
breast tissue [28, 29] and it is unlikely that exactly 100% of
large cancers will be detectable. However, the cut-off size of
≥ 15mmwas chosen as it is a key performance indicator in the
NHSBSP. This is because we have shown in earlier work that
improvements in technology and reading protocols only re-
sulted in the detection of invasive cancers < 15 mm [30]. The
difference between higher and lower quality screening is
therefore there in the detection of these small invasive cancers.
Should a smaller (> 10 mm) or larger (>20 mm) cut-off be
used, we have calculated that the change in the ratio of large
to small grade 3 cancers would change by 5%. This would not
change the overall premise of reduced sensitivity for grade 3
cancers. Our third assumption is that the rate of phenotypic
drift from low to high grade in untreated primary cancers is
small, unlike in treated metastatic or recurrent cancers [31].
Table 2 Prevalent screen association between size grade and nodal status and estimated sensitivity of grade 2 and 3 invasive cancers relative to the
sensitivity for grade 1 invasive cancers
Grade 1 Grade 2 Grade 3 Total
< 15 mm 15 +mm < 15 mm 15 +mm < 15 mm 15 +mm
Invasive cancers (row 1) 2177 1192 2562 3414 682 1414 11,441
Expected < 15 mm if the ratio is the same as
grade 1 (row 2)
2177 6235 (= 3414 × 1.8) 2582 (= 2582–682)
Undetected < 15 mm if ratio same as grade 1
(i.e. 1.8:1) (row 3)
0 3673 (= 6235–2562) 1900 (2582–682)
Detective invasive cancers (row 4) 2177 + 1192 = 3369 2562 + 3414 = 5976 682 + 1414 = 2096
Potential total if sensitivity is the same as for
grade 1 (row 5)
3369 3693 + 5976 = 9649
(row 3 + row 4)
2096 + 1900 = 3996
(row 3 + row 4)
Estimated sensitivity for invasive cancers
relative to grade 1 (row 6)
100% 62% (5976/9649)
100% × row 4/row 5
52%(2096)/(3996)
100% × row 4/row 5
Estimated sensitivity for invasive cancers
(< 15 mm) relative to grade 1
100% 41% (2562/6235) 100% ×
row1/row2
26% (682/2582) 100% × row
1/row 2
Table 3 Screen-detected and interval cancers by grade reported by Porter [8] with our estimates of their absolute and relative sensitivity compared with
our estimate of relative sensitivity from Table 2 and Perron [9]
Porter et al 2007 (ref [8]) This study Perron et al 2018 (ref [9])
Grade Screen detected % Interval% Total Estimated absolute
sensitivity (%)
Relative sensitivity
cf. grade 1 (%)
Relative sensitivity
cf. grade 1 (%)
Relative sensitivity cf.
luminal A
1 157 (34.6) 28 (9.7) 185 85 100 100 Luminal A 100%
2 172 (37.9) 120 (41.5) 292 59 69 62 Luminal B 88% Triple negative 70%
3 125 (27.5) 141 (48.8) 266 47 55 52 60% HER-2 positive
Total 454 289 (100) 743 61
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A significant proportion of the conclusions drawn are
made by extrapolating from the data; however, we believe
that these assumptions are scientifically sensible.
Furthermore, we have validated our estimate of a relative
sensitivity of 62% (grade 2) and 52% (grade 3) using
screen-detected and interval cancers from a large single
English screening centre [8]. Crucially, this validation sug-
gests that our assumptions are reasonable. Similar results
relating to biomarkers are reported from a 2-year Canadian
screening programme [9]. For prevalent screen data, we are
suggesting that the rate of undetected (if we had the same
sensitivity as for grade 1) small (< 15 mm) grade 3 invasive
cancers is 1900 from 2,295,016 women which is 0.83 per
1000. There will also be 1.60 per 1000 undetected small (<
15 mm) grade 2 invasive cancers giving a total of 2.43 per
1000. We (RGB who calculated the original national inter-
val cancers rate targets back in 1994) have estimated the
expected interval cancer rate over the 3-year interval for
prevalent screens only as around 2 per 1000. This is slight-
ly lower than the 2.43 per 1000 and this may reflect the fact
that some missed cancers will not occur as interval cancers,
but be screen detected at the next screen. Finally, the pur-
pose of this paper is twofold: firstly to present the data as in
Table 1 and Fig. 1 and secondly to interpret that data. The
data shown in Fig. 1 clearly show that small grade 3s are
not being detected in large numbers and that this is inde-
pendent of screening interval. This is an observation of
fundamental importance to mammography screening.
Fig. 3 Histogram of grade 3 rate
per 1000 for 80 screening
facilities using data for prevalent
and incident screens combined for
the seven screening years from
2009/2010 to 2015/2016
Fig. 4 Funnel plot of percentage
grade 3 cancers < 15 mm with 90
and 95% control limits around
30% and labelled with grade 3
detection rate for the 80 screening
facilities for prevalent and
incident screens combined for the
seven screening years from 2009/
2010 to 2015/2016
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Changes in screening and cancer detection
The introduction of two-view mammography in the NHSBSP
around the year 2000 increased the detection of invasive can-
cers by allowing indistinct features on one view to be resolved
as irregular masses on a second ([26]. This resulted in a 15–
20% reduction in interval cancers [25]. There has also been an
increase in overall cancer detection by 14% with digital mam-
mography, almost exclusively grade 1 and 2 invasive cancers,
but no change in grade 3. There was a 39% increase in HNG
DCIS detection. There is observational evidence suggesting
that for every 3 extra cases of screen-detected DCIS, one in-
terval cancer is prevented and that this association persists
even after adjustment for small screen-detected cancers [11,
29, 32]. As our study is based on an estimated 65% digital
usage [11] and the impact of digital is to increase detection of
grade 1 and 2 but not grade 3 invasive cancers, then our esti-
mates of the relative sensitivity of grade 3 invasive cancers at
100% digital usage could be considered marginally
conservative.
Challenges with detection of grade 3 cancers
The lack of overall change in grade 3 detection rates with the
introduction of digital mammography and in the percentage of
small grade 3 cancers over time implies that there has been
little change in the last two decades in the detection of small
high-grade invasive cancers. Grade 3 cancers accounted for
18.4% of the total invasive cancers detected in the prevalent
round and 20.9% in the incident round. This contrasts with
48.8% of interval cancers being grade 3 [8], which is in line
with a calculated relative screening sensitivity for high-grade
cancers of around 50%. The radiological features of more
aggressive cancers are described as subtle, including masses
with indistinct margins and fine linear calcification. Round or
oval aggressive malignant masses with well-circumscribed
margins can mimic benign lesions [33, 34]. These features
may explain the low sensitivity for high-grade tumours; i.e.
fast-growing invasive cancers do not exhibit mammographic
features such as calcifications associated with cancer [35]. In
addition, the short doubling time of grade 3 lesions [36] may
lead to them growing and becoming clinically detectable be-
tween screens and thus increase the likelihood of presentation
as interval cancers. The majority of grade 3 invasive cancers
therefore appear without any prior warning even if there is a
prior screen. This tallies with the body of evidence that sug-
gests that the majority of interval cancers are true interval or
occult interval breast cancers that were not visible on the index
screen [37].We infer that many small grade 3 invasive cancers
are mammography invisible; for example, they have the same
density as the surrounding tissue and no additional features
such as spiculations or calcifications.
Generalisability of this study
The NHSBSP offers 3 yearly mammography which may in-
crease both screen cancer detection rates and interval cancer rates
in comparison with countries with annual and biennial screening
programmes. The findings at the prevalent screen however will
be generalisable to other mammographic screening programmes.
Our findings at incident screens are not directly generalizable to
screening programmes with different screen intervals. However,
our findings may also be important because if small grade 3
invasive cancers are not detectable, then they will still be
underrecognised using a 2-year or even a 1-year interval.
The effect of recall rate
In England, observational data suggests increasing recall rate
is not the answer to the poor sensitivity of mammography for
high-grade cancers. There is a threshold maximum recall rate
which is modelled to allow detection of 99% of the screen-
detectable cancers in the NHSBSP, which is 7% at the prev-
alent screen and 4% at incident screen [38]. Above this recall
rate, very few extra cancers are found, mainly low- and
intermediate-grade DCIS.
Is there a role for new technology?
Despite the difficulties of finding small grade 3 cancers, mam-
mography screening still reduces mortality. Any further im-
provement in mortality reduction requires finding proportion-
ally more grade 3 cancers when small. This is doubly difficult
because of morphology i.e. a lack of mammographic features
when small and biology, as the doubling time of grade 3
cancers onmammography is approximately a third of the dou-
bling time of grade 1 cancer with an average of 105 days vs
average of 353 days [34] or 128 vs 194 [39].
To date, digital mammography has preferentially increased
the detection of lower risk disease [11], but does bring the
advantage of post processing which could be used to maxi-
mise soft tissue lesion detection [40]. Some types of post
processing of digital raw images may favour the detection of
spiculations and calcifications over soft tissue lesions and ben-
efit the detection of lower, rather than higher grade invasive
cancers, as well as ductal carcinoma in situ (DCIS). The se-
lection of post processing algorithms to enhance soft tissue
could lead theoretically to an increase in detection of subtle,
but not necessarily high-risk malignancies.
Tomosynthesis certainly increases cancer detection, but the
additional cancers are predominantly low grade [15, 41] and
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to date, there has been no impact on interval cancer rates [12,
42]. The additional detection of small grade 3 cancers is un-
clear, as grade size distribution has not been reported, but
current evidence does not suggest that this is the answer to
increasing the detection of small fast growing cancers destined
to become interval cancers.
Supplemental ultrasound, which uses different biological
imaging properties, for dense breasts identifies more cancers,
but again these do not appear to be preferentially high grade
resulting in minimal impact on interval cancer rates [43].
Functional imaging might help as interval cancers show
higher mitotic rates and angiogenesis than screen-detected
ones [22], and there is evidence that MRI is much better at
detecting cancers of high nuclear grade [44]. Along withMRI,
another promising new imaging method is contrast enhanced
spectral mammography (CESM) which has a similar sensitiv-
ity and specificity to MRI [45]. The DENSE trial has not yet
published grade size distribution but in those 10% of women
with the highest breast density, there was a significant fall in
interval cancer rates suggesting that MRI may be a more sen-
sitive screening test for high-grade cancers. However, signif-
icant numbers of additional grade 1 and grade 2 together with
benign and indeterminate lesions were also detected [46].
Conclusion
This study has demonstrated poor relative sensitivity of
screening mammography for the detection of small invasive
grade 3 cancers. This is likely to be related to both the poor
visibility of high-grade invasive cancers when small as well as
the short doubling time. Despite the fact that this mammo-
graphic screening has shown a significant mortality reduction,
any further improvement in technology or process needs to
concentrate on the detection of smaller grade 3 cancers.
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